Table 3.

Treatment profile and efficacy ( n  = 6)

Patient no.	#02	#03	#04	#05	#06	#07
Dose reduction of SMILE (course)	l‐Asp: 7→4 times (2nd)	l‐Asp: reduced at a dose of 50% (2nd)	–	l‐Asp: 7→4 times (1st)	–	–
Delay of the second course of SMILE	–	7 days	–	–	2 days	2 days
Planned treatment	Terminated	Completed	Terminated	Completed	Completed	Completed
Overall response	NE	CR	NR	PR	CR	CR
Additional treatment	–	SMILE × 1, SMI(L)E × 1 for PBSCH, HD‐auto PBSCT	DeVIC × 1	SMILE × 1, HD‐ETP for PBSCH, HD‐auto PBSCT	MILD × 2, HD‐ETP for PBSCH, MILD × 1, HD‐auto PBSCT	SMILE × 4 (from 4th course, E. coli l‐Asp was switched to Erwinia l‐Asp)
Outcome	TRD, 2M	AND, 15M	DOD, 3M	AWD, 7M	AND, 7M	AND, 7M

AND, alive with no evidence of disease; AWD, alive with disease; CR, complete response; DeVIC, dexamethasone, etoposide, ifosfamide, carboplatin; DOD, died of disease; ETP, etoposide; HD, high dose; M, months after registration; MILD, methotrexate, ifosfamide, l‐asparaginase, dexamethasone; NE, not evaluable; NR, no response; PBSCH, peripheral blood stem cell harvest; PBSCT, peripheral blood stem cell transplantation; PR, partial response; SMI(L)E, dexamethasone, methotrexate, ifosfamide, etoposide; SMILE, dexamethasone, methotrexate, ifosfamide, l‐asparaginase, etoposide; TRD, treatment‐related death.